In 2021, Sanjaya Singh, known for his contributions in immunology and oncology, left Johnson & Johnson. His former colleague, Peter Lebowitz, was intrigued and considered a potential partnership. However, Singh and venture capital firm Omega Funds proposed a different idea to Lebowitz: to join their new biotech company as CEO. Lebowitz found the opportunity compelling and described it as a “no-brainer.” This move signaled a shift in Singh’s career trajectory and highlighted the potential for growth and success in the new venture.
Source link
Biotech launches with $165 million for cancer, autoimmune therapies
